Nicotinamide adenine dinucleotide

Hydreight Reports Record Revenue in Q3 2023

Retrieved on: 
Tuesday, November 21, 2023
NURS, Pain management, Metabolism, Pharmacy, Telehealth, City, Nicotinamide adenine dinucleotide, Legislation, NAD, LAS, Nursing, Ageing, Nucleotide, Growth, Overalls, GAAP, YTD

Q3 2023 record topline1 revenue of $3.97 million, YTD topline1 revenue of $12.06 million.

Key Points: 
  • Q3 2023 record topline1 revenue of $3.97 million, YTD topline1 revenue of $12.06 million.
  • Q3 2023 GAAP revenue was $3.09 million, an increase of 172% compared to Q3 2022.
  • Shane Madden, CEO of Hydreight commented, “Q3 2023 was an excellent quarter for Hydreight and our financial results reflect the continued organic growth across all our divisions and diverse revenue mix.
  • On October 5, 2023, Hydreight provided a corporate update reflecting significant revenue growth and strong organic operational growth.

A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)

Retrieved on: 
Thursday, November 30, 2023
Health, Neurology, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Brain, Safety, Research, Deficit spending, Parkinson's disease, Cell Metabolism, ChromaDex, Disease, Tremor, Stiffness, Nicotinamide adenine dinucleotide, Neuron, Nature Communications, Agonal respiration, Dementia, University, Person, Mitochondrion, Translational research, Haukeland University Hospital, University of Bergen, NAD, Pharmaceutical industry, Medical device, PD

These results build upon previous research led by Dr. Tzoulis ( Cell Metabolism ) and showcase that supplementation with Niagen NR may be a therapeutic strategy for PD, pending further research.

Key Points: 
  • These results build upon previous research led by Dr. Tzoulis ( Cell Metabolism ) and showcase that supplementation with Niagen NR may be a therapeutic strategy for PD, pending further research.
  • Current treatment options are limited, and there is a pressing need for innovative approaches to manage the effects of this debilitating neurodegenerative disorder.
  • This study establishes the short-term safety of 3,000 mg NR daily and allows the clinical community to explore high-dose options in future therapeutic trials.
  • Notably, all of Prof. Tzoulis’ clinical research is academically-driven and based largely on public funding.

Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients

Retrieved on: 
Wednesday, November 15, 2023
Science, Other Science, Research, Public Relations, Investor Relations, General Health, Health, Communications, Clinical Trials, De Veenhuis, Movement disorder, DNA, CERP, Oculomotor apraxia, ChromaDex, Liver, Clinical trial, Cerebellar degeneration, Patient, Multimedia, Nicotinamide adenine dinucleotide, Immunodeficiency, Movement, DNA repair, Cerebellar ataxia, Cognition, Eye, University, Trial of the century, University of Oslo, Biomarker, NAD, Medical device, Ataxia–telangiectasia

The promising results demonstrate that long-term supplementation with Niagen NR effectively increased whole blood NAD+ levels up to fourfold, improved coordination, and enhanced eye movement while maintaining biomarkers of stable liver and kidney function in Ataxia Telangiectasia (AT) patients.

Key Points: 
  • The promising results demonstrate that long-term supplementation with Niagen NR effectively increased whole blood NAD+ levels up to fourfold, improved coordination, and enhanced eye movement while maintaining biomarkers of stable liver and kidney function in Ataxia Telangiectasia (AT) patients.
  • AT is a rare, inherited neurodegenerative disorder characterized by premature aging, cerebellar degeneration, immunodeficiency, and cancer predisposition.
  • View the full release here: https://www.businesswire.com/news/home/20231115900463/en/
    Newly published phase II clinical study demonstrates that supplementation with Niagen, patented nicotinamide riboside (NR), elevates NAD+ up to fourfold, improving motor coordination and eye movement in Ataxia Telangiectasia (AT) patients (Graphic: Business Wire)
    Building on a growing body of research, this is the second published study ( Veenhuis et al.
  • This growing body of research is promising as it demonstrates that NR supplementation may be a potential therapeutic strategy for AT patients.”

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023

Retrieved on: 
Thursday, November 9, 2023
Biotechnology, General Health, Health, Science, Research, NAD, Nicotinamide adenine dinucleotide, ChromaDex, Google Chrome

ChromaDex welcomes stakeholders, investors, and other individual followers to register and attend these live events.

Key Points: 
  • ChromaDex welcomes stakeholders, investors, and other individual followers to register and attend these live events.
  • The presentations will feature Rob Fried, Chief Executive Officer, and Brianna Gerber, Chief Financial Officer.
  • Topics to be covered will include the latest investor presentation followed by a live Q&A.
  • Investors interested in participating in either of these events will need to register using the links below.

ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide

Retrieved on: 
Wednesday, November 1, 2023
Vitamins, Supplements, Other Retail, Marketing, Fitness & Nutrition, Communications, Specialty, Health, Retail, Influencer, OBGYN, Nicotinamide adenine dinucleotide, Ageing, NSF International, Major League Baseball, Senior ice hockey, Depression, NAD, Internet, Physician, ChromaDex, National Hockey League, Host, Bureau of Oceans and International Environmental and Scientific Affairs, Research, Multimedia, Senior, MLB, USADA, Nobel Prize, NHL, Safety, NR, Dietary supplement, Medical device, Nicotinamide riboside, RD, Habit

ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) research and healthy aging, launches its clinical strength Tru Niagen® Pro 1,000mg , featuring 1,000mg of Niagen® (patented Nicotinamide Riboside or NR), one of the most efficient and superior quality NAD+ precursors on the market, to consumers nationwide.

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) research and healthy aging, launches its clinical strength Tru Niagen® Pro 1,000mg , featuring 1,000mg of Niagen® (patented Nicotinamide Riboside or NR), one of the most efficient and superior quality NAD+ precursors on the market, to consumers nationwide.
  • With 1,000mg of Niagen used in over 50% of published clinical studies, this serving is redefining research for NAD+ related health outcomes.
  • “As a pioneer of NAD+ research, our team works with esteemed investigators across the globe to uncover the full potential of NAD+.
  • Tru Niagen Pro 1,000mg was unveiled to a select group of Key Opinion Leaders (KOLs), physicians, influencers and celebrities at the Tru Niagen Wellness Retreat in Malibu last week.

ALZINC and NEXUS LIFE SCIENCES LAB INC. Unveil the Norige Youth Initiative, a Game-Changer in the Realm of Anti-Aging Technology

Retrieved on: 
Monday, October 23, 2023
Science, Nicotinamide adenine dinucleotide, Nicotinamide riboside, Research, Ageing, Health, Realm, NEXUS, Biotechnology, NAD, Agonal respiration, Data science, Calcium signaling, Society, LAB, DNA repair, Calendar, NR, Longevity, DNA, Pharmaceutical industry

ALZINC and NEXUS LIFE SCIENCES LAB INC. have introduced the Norige Youth Initiative, a pioneering global consortium that seeks to revolutionize anti-aging technology with the potential to extend the human lifespan and transform the societal and economic approach to aging and wellness.

Key Points: 
  • The Norige Youth Initiative is set to revolutionize our understanding of aging and promises to be a game-changer in the realm of anti-aging technology.
  • ALZINC and NEXUS LIFE SCIENCES LAB INC.
  • Unveil the Norige Youth Initiative, a Game-Changer in the Realm of Anti-Aging Technology
    To view an enhanced version of this graphic, please visit:
    This initiative represents a paradigm shift in the field of anti-aging research.
  • In unveiling the Norige Youth Initiative, ALZINC and NEXUS LIFE SCIENCES LAB INC. have embarked on a transformative journey in anti-aging technology.

Hydreight Launches NAD+ as Part of Robust Patient Service Offering

Retrieved on: 
Thursday, October 19, 2023
Nicotinamide adenine dinucleotide, LAS, Ageing, Health, NAD, Metabolism, Nucleotide, FSE, Pain management, Investment, Nursing, Patient

Hydreight is building the largest mobile clinical network in the United States for nurses to provide at- home healthcare services across 50 states.

Key Points: 
  • Hydreight is building the largest mobile clinical network in the United States for nurses to provide at- home healthcare services across 50 states.
  • The Company plans to continue adding products to its offering and will be launching lab testing and patient specific services in the next few months.
  • In order to start providing NAD+ services, Hydreight has customized its proprietary technology and updated the workflows across every state.
  • Shane Madden, CEO of Hydreight commented, “This is another significant milestone for the evolution and expansion of the Company.

Solgar® Cellular Nutrition Emerges to Take Longevity Cell Deep

Retrieved on: 
Tuesday, October 24, 2023
Nicotinamide adenine dinucleotide, Nicotinamide riboside, Science, Ageing, Scientific Reports, NAD, Food, Biomarker, Food and Drug Administration, Research, Cell, UA, RCT, Exercise, Development, Dietary supplement, Leg, JAMA Network Open, The Bountiful Company, Disease, Clinical trial, Urolithin A, Hand, Cysteine, Nutrient, Randomized controlled trial, NR, Oxidative stress, Longevity, Mobile phone, Glycine

HOBOKEN, N.J., Oct. 24, 2023 /PRNewswire/ -- Solgar®, a Nestlé Health Science brand and a leader in scientifically-backed vitamin and nutritional supplements for more than 70 years, today unveiled its Solgar® Cellular Nutrition line of dietary supplements developed to help fight cellular decline and promote cell health. Solgar Cellular Nutrition's products – Energy, Strength & Renewal, and Protect – target cellular decline through clinically studied ingredients, including Nicotinamide Riboside (NR), Urolithin A (UA) as well as Glycine & N-Acetyl Cysteine (GlyNAC). These products are available online through Solgar Cellular Nutrition at www.solgar.com/cellular-nutrition.  

Key Points: 
  • These products are available online through Solgar Cellular Nutrition at www.solgar.com/cellular-nutrition .
  • "These scientific advances along with new cellular nutrition research led us to develop our new line of Solgar Cellular Nutrition products.
  • These products – Energy, Strength & Renewal, and Protect – feature nutrients that work with the body's natural processes deep inside cells to help fight sources of cellular decline and promote overall cell health.
  • To learn more about Solgar Cellular Nutrition and purchase its cellular health products, please visit www.solgar.com/cellular-nutrition .

A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients

Retrieved on: 
Monday, October 2, 2023
Research, General Health, Pharmaceutical, Consumer, Fitness & Nutrition, Clinical Trials, Science, Biotechnology, Seniors, Alternative Medicine, Vitamins, Supplements, Health, Exercise, DNA, Human, Nicotinamide adenine dinucleotide, Diabetes, Metabolism, NR, Nicotinamide riboside, Cardiovascular disease, ATP, Clinical trial, Ageing, NAD, ChromaDex, National Heart, Lung, and Blood Institute, Inflammation, Cell, Lung, Lupus, Bangladesh Technical Education Board, Trial of the century, Psoriasis, Amna Elhassan, NHLBI, Patient, Polyphosphate, Sleep deprivation, Conditional sentence, Smoking, Adenosine triphosphate, MRC Mitochondrial Biology Unit, NIH, Cell Reports, DNA repair, Pharmaceutical industry, Dietary supplement

The clinical trial was part of the ChromaDex External Research Program (CERP™), which donated ChromaDex’s patented nicotinamide riboside (NR) ingredient, Niagen, for the advancement of this research.

Key Points: 
  • The clinical trial was part of the ChromaDex External Research Program (CERP™), which donated ChromaDex’s patented nicotinamide riboside (NR) ingredient, Niagen, for the advancement of this research.
  • This is Dr. Sack’s fourth published study on NR, and the seventh clinical study overall, that demonstrates NR’s effectiveness in reducing inflammation, an important indicator of how the body is aging,” remarked Rob Fried, CEO of ChromaDex.
  • This is the third published human clinical study demonstrating that NR supplementation has a protective effect in healthy individuals and lays the foundation for future clinical research ( Elhassan et al.
  • Research suggests a depletion of NAD+ is associated with impaired inflammatory responses and innate immune dysfunction, indicating NAD+ levels may have a critical impact on the function of immune cells.

Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMN

Retrieved on: 
Thursday, August 24, 2023
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, ENT, Human, Nicotinamide adenine dinucleotide, Cell membrane, Diet, Metabolism, Ageing, NMN, NAD, Multimedia, CD73, ChromaDex, Ivan Kropotov, Edward Conze, Assistant, Protein, Molecular genetics, G.H. Raisoni Department of Microbiology and Biotechnology, Canadian International Council, Weill Cornell Medicine, Mouse, Nicotinamide mononucleotide, International Journal of Molecular Sciences, UCLA, Isotope, Environmental Molecular Sciences Laboratory, Pharmaceutical industry, Phosphorus, Immunology, Pharmacology

The results indicate that NMN is primarily converted to nicotinamide and nicotinamide riboside (NR) before being utilized for NAD+ synthesis, with only a small portion of NMN being directly incorporated into NAD+.

Key Points: 
  • The results indicate that NMN is primarily converted to nicotinamide and nicotinamide riboside (NR) before being utilized for NAD+ synthesis, with only a small portion of NMN being directly incorporated into NAD+.
  • These results build on a growing body of research demonstrating that NMN cannot cross the cell membrane directly and must first be converted to NR.
  • Because NR can cross the cell membrane directly, this data, along with other science, indicates that NR is a more efficient NAD+ precursor than NMN.
  • NR and NMN are chemically identical except for a phosphate group present within the structure of NMN.